分子肿瘤学国家重点实验室焦宇辰研究组，长期围绕肿瘤临床诊疗的核心问题，主要从事消化系统和神经系统恶性肿瘤的癌症基因组、分子分型及无创活检研究，筛选可用于临床诊疗的分子标志物。 课题组目前具有正研究员1人，副研究员2人，主管技师和技师各1人，硕士、博士研究生若干。

在研项目：

1、国家自然科学基金面上项目，82372696、MEN1通过代谢重编程介导ATRX功能改变促进胰腺神经内分泌肿瘤进展的机制研究、2024/1/1-2027/12/31、49万元。（课题负责人）

2、国家自然科学基金面上项目，82172988、芳香烃受体介导黄曲霉毒素诱发肝细胞癌变的功能机制、2022/1/1-2025/12/31、54.8万元。（课题负责人）

3、国家重点研发计划项目课题，2020YFC2002705、主动健康和老龄化科技应对、2020/1/1-2022/12/31、125万元。（子课题负责人）

4、中国医学科学院医学与健康科技创新工程，2021-I2M-1-014、转移性乳腺癌精准诊疗关键技术与临床应用研究、2021/1/1-2025/12/31、80万元。（子课题负责人）

(1) Chen Z#, Wang X#, Jin Z#, Li B#, Jiang D, WangY, Jiang M, Zhang D, Yuan P, Zhao Y, Feng F, Lin Y, Jiang L, Wang C, Meng W, YeW, Wang J, Qiu W, Liu H, Huang D, Hou Y, Wang X, Jiao Y*, Ying J*, Liu Z*, LiuY*. Deep learning on tertiary lymphoid structures in hematoxylin-eosin predictscancer prognosis and immunotherapy response. NPJ Precis Oncol. 2024;8(1):73.

(2) Fan XH#, Zhang Y#, Wang P, Song QQ, Wang M,Mejias-Luque R, Li ZX, Zhou T, Zhang JY, Liu WD, Zhang LF, Li WQ, You WC,Gerhard M, Jiao YC, Wang XB*, Pan KF*. A noninvasive multianalyticalapproach establishment for risk assessment and gastric cancer screening. Int JCancer. 2024;154(6):1111-1123.

(3) Zhu Q#, Zhang Y#, Li M, Zhang Y, Zhang H, Chen J, LiuZ, Yuan P*, Yang Z*, Wang X*. MiR-124-3p impedes the metastasis ofnon-small cell lung cancer via extracellular exosome transport andintracellular PI3K/AKT signaling. Biomark Res. 2023;11(1):1.

(4) Du Y#, Ma Y#, Zhu Q, Fu Y, Li Y, Zhang Y, Li M, Feng F*,Yuan P*, Wang X*. GDF15 negatively regulates chemosensitivity viaTGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinoma. FrontMed.2023;17(1):119-131.

(5) Ma Y#, Zhu Q#, Wang X#, Liu M, Chen Q, Jiang L,Chi Y, Zeng YX*, Zhao H*, Jiao Y*. Synthetic lethal screening identifies DHODHas a target for MEN1-mutated tumor cells. Cell Res. 2022;32(6):596-599.

(6) Zhu Q#, Ma Y#, Liang J#, Wei Z#, Li M, Zhang Y, Liu M,He H, Qu C, Cai J, Wang X*, Zeng Y*, Jiao Y*. AHR mediates the aflatoxinB1 toxicity associated with hepatocellular carcinoma. Signal Transduct TargetTher. 2021;6(1):299.

(7) Du Y, Ma Y, Zhu Q, Liu T, Jiao Y, Yuan P*, WangX*. An m6A-Related Prognostic Biomarker Associated With the HepatocellularCarcinoma Immune Microenvironment. Front Pharmacol. 2021;12:707930.

(8) Yin H#, Yang L#, Peng G, Yang K, MiY, Hu X, Hao X, Jiao Y, WangX*, Wang Y*.The commensal consortium of the gut microbiome is associatedwith favorable responses to anti-programmed death protein 1 (PD-1) therapy inthoracic neoplasms. Cancer Biol Med. 2021 ;18(4):1040-1052.

(9) Ma Y#, Zhu Q#, Liang J, Li Y, Li M, Zhang Y, Wang X*, Zeng Y*, Jiao Y*.A CRISPR knockout negative screen reveals synergybetween CDKs inhibitor andmetformin in the treatment of human cancer in vitroand in vivo. Signal TransductTarget Ther. 2020; 5(1):152.

(10) Ma Y#, He S#, Gao A#, Zhang Y#, Zhu Q, Wang P, Yang B, Yin H, Li Y, Song J, Yue P, Li M, Zhang D, Liu Y, Wang X*, Guo M*, Jiao Y*.Methylation Silencing of TGF-β Receptor Type II Is InvolvedinMalignant Transformation of Esophageal Squamous Cell Carcinoma. ClinEpigenetics. 2020;12(1):25.